Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DRAMATIC Trial for MDR-TB
NCT03828201Phase 2Active, not recruiting
- Sponsor
- Boston University
- Start
- Jun 2022
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of bedaquiline, delamanid, levofloxacin, linezolid, clofazimine in multidrug-resistant tuberculosis (MDR-TB), sponsored by Boston University. Started Jun 2022; status: active, not recruiting.
02
Drugs
bedaquilinedelamanidlevofloxacinlinezolidclofazimine
03
Conditions
multidrug-resistant tuberculosis (MDR-TB)
Beyond the preview
Go deeper on NCT03828201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03828201.